You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Article metrics

Article menu

Download PDFPDF

Research Article
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

 

Online download statistics by month:

Online download statistics by month: December 2019 to July 2025

AbstractFullPdf
Dec 2019441
Jan 202015151
Feb 202024248
Mar 2020606012
Apr 20201021022
May 202010310318
Jun 2020383810
Jul 202040409
Aug 202032327
Sep 2020595914
Oct 202010410448
Nov 2020575729
Dec 2020999925
Jan 2021717121
Feb 2021484814
Mar 2021797931
Apr 2021858530
May 2021838337
Jun 2021808020
Jul 2021646418
Aug 2021717119
Sep 2021798031
Oct 2021707037
Nov 2021959539
Dec 2021646619
Jan 202282877
Feb 202212012220
Mar 2022879126
Apr 202211211429
May 202211111621
Jun 2022799225
Jul 2022818212
Aug 2022707820
Sep 202227127922
Oct 2022678133
Nov 202211211328
Dec 202212212414
Jan 2023919121
Feb 202310310526
Mar 202312112430
Apr 2023798125
May 2023787924
Jun 2023707416
Jul 2023818127
Aug 2023707024
Sep 2023798222
Oct 202312812816
Nov 202331031418
Dec 202311511527
Jan 2024828417
Feb 202415815926
Mar 202411612034
Apr 202410510639
May 2024747615
Jun 2024979635
Jul 202411111432
Aug 2024787722
Sep 2024788024
Oct 2024808020
Nov 202411511628
Dec 202434334628
Jan 202513413645
Feb 202523823833
Mar 202512412537
Apr 202520020136
May 202510210341
Jun 2025595918
Jul 2025330
Total656266711563